PMID- 35403359
OWN - NLM
STAT- MEDLINE
DCOM- 20221013
LR  - 20221104
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 11
IP  - 19
DP  - 2022 Oct
TI  - Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for 
      unresectable hepatocellular carcinoma: A multicenter retrospective study.
PG  - 3612-3622
LID - 10.1002/cam4.4747 [doi]
AB  - BACKGROUND: Immunotherapy-antiangiogenesis combination therapy has achieved 
      excellent survival outcomes in hepatocellular carcinoma (HCC) in clinical trials. 
      However, the combination therapy for HCC outside clinical trials is not well 
      studied, and predictive factors are lacking. Here, we retrospectively analyzed 
      the efficacy and safety of immunotherapy-antiangiogenesis combination therapy in 
      unresectable HCC patients in a real-world setting. METHODS: We conducted a 
      four-center, retrospective study of unresectable HCC patients who received the 
      combination of programmed death 1 (PD-1) inhibitor and antiangiogenic agent 
      between April 2018 and July 2021 in China. RESULTS: In total, 136 patients were 
      enrolled in the cohort. The objective response rate (ORR) and disease control 
      rate (DCR) were 38.0% and 81.8%, respectively. The median time to progression 
      (TTP), progression-free survival (PFS), and overall survival (OS) were 7.2, 7.3, 
      and 19.6 months, respectively. The multivariate analysis indicated that ECOG 
      performance status score (PS) 2 was a significantly independent negative factor 
      of ORR. Moreover, ECOG PS 2, peritoneum metastasis and previous immunotherapy 
      were found to be independent negative predictors of PFS. A shorter OS was 
      associated with ECOG PS 2, peritoneum metastasis, the presence of previous 
      immunotherapy, Child-Pugh stage B, and high alpha-fetoprotein (AFP) 
      concentration. One hundred and twenty-five patients (91.9%) reported adverse 
      events (AEs) with any grade. CONCLUSION: We elucidated the efficacy and safety of 
      immunotherapy-antiangiogenesis combination therapy and identified potential 
      predictors for response and survival in a real-world cohort of patients with 
      unresectable HCC.
CI  - (c) 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
FAU - Yao, Junlin
AU  - Yao J
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Zhu, Xudong
AU  - Zhu X
AD  - Department of Medical Oncology, The First Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Wu, Zhiheng
AU  - Wu Z
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Wei, Qing
AU  - Wei Q
AD  - Department of Medical Oncology, Cancer Hospital of the University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
FAU - Cai, Yibo
AU  - Cai Y
AD  - Department of Colorectal Surgery, Cancer Hospital of University of Chinese 
      Academy of Sciences, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China.
FAU - Zheng, Yu
AU  - Zheng Y
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Hu, Xinyu
AU  - Hu X
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Hu, Hong
AU  - Hu H
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Zhang, Xiangyu
AU  - Zhang X
AD  - Department of General Surgery, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Pan, Hongming
AU  - Pan H
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Zhong, Xian
AU  - Zhong X
AUID- ORCID: 0000-0001-5915-5531
AD  - Department of Medical Oncology, The Second Affiliated Hospital, College of 
      Medicine, Zhejiang University, Hangzhou, Zhejiang, China.
FAU - Han, Weidong
AU  - Han W
AUID- ORCID: 0000-0001-7227-3671
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, College of Medicine, 
      Zhejiang University, Hangzhou, Zhejiang, China.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20220410
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (alpha-Fetoproteins)
SB  - IM
MH  - Angiogenesis Inhibitors/adverse effects
MH  - *Carcinoma, Hepatocellular/drug therapy/pathology
MH  - Humans
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Liver Neoplasms/pathology
MH  - Programmed Cell Death 1 Receptor
MH  - Retrospective Studies
MH  - alpha-Fetoproteins
PMC - PMC9554456
OTO - NOTNLM
OT  - angiogenesis
OT  - hepatocellular carcinoma
OT  - immunology
OT  - prognosis
OT  - prognostic factor
COIS- The authors declared no potential conflict of interest.
EDAT- 2022/04/12 06:00
MHDA- 2022/10/14 06:00
PMCR- 2022/04/10
CRDT- 2022/04/11 05:35
PHST- 2022/03/01 00:00 [revised]
PHST- 2021/12/15 00:00 [received]
PHST- 2022/04/01 00:00 [accepted]
PHST- 2022/04/12 06:00 [pubmed]
PHST- 2022/10/14 06:00 [medline]
PHST- 2022/04/11 05:35 [entrez]
PHST- 2022/04/10 00:00 [pmc-release]
AID - CAM44747 [pii]
AID - 10.1002/cam4.4747 [doi]
PST - ppublish
SO  - Cancer Med. 2022 Oct;11(19):3612-3622. doi: 10.1002/cam4.4747. Epub 2022 Apr 10.